Krystal Biotech, Inc. (NASDAQ:KRYS) Given Average Recommendation of "Moderate Buy" by Brokerages

Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven ratings firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $209.00.

Several analysts have recently issued reports on the company. Bank of America reduced their price objective on Krystal Biotech from $193.00 to $192.00 and set a "buy" rating on the stock in a research note on Tuesday, July 22nd. Citigroup reiterated a "neutral" rating and issued a $166.00 price objective (down from $176.00) on shares of Krystal Biotech in a research note on Tuesday, August 5th. HC Wainwright reiterated a "buy" rating and issued a $240.00 price objective on shares of Krystal Biotech in a research note on Friday, August 22nd. Finally, Chardan Capital reduced their price objective on Krystal Biotech from $219.00 to $216.00 and set a "buy" rating on the stock in a research note on Friday, August 22nd.

Insider Activity

In other Krystal Biotech news, insider Suma Krishnan sold 1,389 shares of the firm's stock in a transaction on Wednesday, July 16th. The stock was sold at an average price of $150.00, for a total value of $208,350.00. Following the sale, the insider directly owned 1,508,056 shares in the company, valued at $226,208,400. This trade represents a 0.09% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 49,800 shares of company stock valued at $7,487,943 in the last 90 days. 13.70% of the stock is currently owned by company insiders.

Institutional Trading of Krystal Biotech

A number of hedge funds and other institutional investors have recently bought and sold shares of KRYS. Brooklyn Investment Group raised its stake in Krystal Biotech by 291.7% in the first quarter. Brooklyn Investment Group now owns 141 shares of the company's stock valued at $25,000 after buying an additional 105 shares in the last quarter. Hantz Financial Services Inc. raised its stake in Krystal Biotech by 8,950.0% in the second quarter. Hantz Financial Services Inc. now owns 181 shares of the company's stock valued at $25,000 after buying an additional 179 shares in the last quarter. Twin Tree Management LP acquired a new stake in Krystal Biotech in the first quarter valued at $29,000. Fifth Third Bancorp raised its stake in Krystal Biotech by 159.1% in the first quarter. Fifth Third Bancorp now owns 171 shares of the company's stock valued at $31,000 after buying an additional 105 shares in the last quarter. Finally, First Horizon Advisors Inc. raised its stake in Krystal Biotech by 212.8% in the second quarter. First Horizon Advisors Inc. now owns 244 shares of the company's stock valued at $34,000 after buying an additional 166 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Stock Performance

Shares of KRYS traded up $5.77 during midday trading on Monday, hitting $143.23. 133,616 shares of the stock were exchanged, compared to its average volume of 326,177. Krystal Biotech has a 52-week low of $122.80 and a 52-week high of $207.84. The stock has a fifty day simple moving average of $146.77 and a 200 day simple moving average of $153.30. The firm has a market cap of $4.14 billion, a P/E ratio of 29.04 and a beta of 0.66.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported $1.29 EPS for the quarter, topping the consensus estimate of $1.08 by $0.21. The business had revenue of $96.04 million during the quarter, compared to analyst estimates of $95.42 million. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%. As a group, equities research analysts forecast that Krystal Biotech will post 6.14 EPS for the current fiscal year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).